Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown
evidence of efficacy in reducing the risk of death among men with metastatic castration …

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

Simple Summary Breast and prostate cancers are serious public health issues that create
considerable burden to both people and healthcare systems worldwide. Cancer is a …

Prostate cancer is the most common malignancy in men, and remains the second leading
cause of cancer-related death in this gender [1]. Data suggests that 10–20% of patients with …

Purpose To update eligibility and outcome measures in trials that evaluate systemic
treatment for patients with progressive prostate cancer and castrate levels of testosterone …

PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …

Purpose Reports have suggested that metastatic site is an important predictor of overall
survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these …

Purpose Prognostic models for overall survival (OS) for patients with metastatic castration-
resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in …

Background Intermediate or surrogate endpoints for survival can shorten time lines for drug
approval. We aimed to assess circulating tumour cell (CTC) count as a prognostic factor for …

Purpose: The summary presented herein represents Part II of the two-part series dedicated
to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …